Pembrolizumab, USFDA
Enfortumab vedotin-ejfv tare da pembrolizumab an amince da su daga USFDA don ci gaba na gida ko na ciwon daji na urothelial
Feb 2024: Hukumar Abinci da Magunguna ta haɓaka aiwatar da amincewar magunguna guda biyu, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) da pembrolizumab (Keytruda, Merck). Wadannan magungunan ana nufin su yi wa mutanen da ke cikin gida..
BMS, Bristol Myers Squibb, immunotherapy, metastatic melanoma, nivolumab da relatlimab, nivolumab da relatlimab-rmbw, Opdualag, USFDA
Farkon LAG-3-Tsarin hanawar rigakafin jiki, Opdualag ™ (nivolumab da relatlimab-rmbw), FDA ta amince da su ga marasa lafiya da ke da melanoma da ba a sake su ba.
Afrilu 2022: Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) ta amince da Opdualag (nivolumab da relatlimab-rmbw), sabon, ƙayyadaddun ƙayyadaddun adadin kashi na farko na nivolumab da relatlimab waɗanda ake gudanarwa azaman jiko guda ɗaya, f..
BMS, Breyanzi, Mota-T Ciwon ƙwayar cuta, T-Cell CAR, CART far, USFDA
Breyanzi - Sabon C-T-Cell far daga BMS
Yuli 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), wani labari CD19-directed chimeric antigen receptor (CAR) T cell magani wanda Bristol Myers Squibb (BMS) ya haɓaka, Hukumar Abinci da Magunguna ta Amurka (US.
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, KARANTA, USFDA
Pembrolizumab ya amince da FDA don adjuvant magani na melanoma
A ranar 15 ga Fabrairu, 2019, Hukumar Abinci da Magunguna ta amince da pembrolizumab (KEYTRUDA, Merck) don kula da marasa lafiya tare da melanoma tare da shigar da kumburin lymph bayan cikakken resection. Amincin ya..
Ablynx, ADAMUTA 13, CABLIVI, caplacizumab-yhdp, FDA, immunosuppressive far, USFDA
Caplacizumab-yhdp ta amince da FDA
A ranar 6 ga Fabrairu, 2019, tare da musayar plasma da maganin rigakafi, Cibiyar Abinci da Magunguna ta amince da caplacizumab-yhdp (CABLIVI, Ablynx NV) ga marasa lafiya manya da suka samu thrombotic thrombocytopeni ..
CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, carcinoma hepatocellular, Sorafenib, USFDA
Cabozantinib an yarda da FDA don ciwon hanta na hanta
A ranar 14 ga Janairu, 2019, Cabozantinib (CABOMETYX, Exelixis, Inc.) ya amince da Hukumar Abinci da Magunguna don marasa lafiya da ciwon hanta (HCC) waɗanda a baya aka yi musu magani tare da sorafenib. A appr..
Akalabrutunib, Avelumab, CART far, Dabrafanib, Kimiya, Sabbin magunguna, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Sabbin magunguna na maganin cutar kansa
Yuli 2021: Duba sabbin magunguna a cikin maganin cutar kansa. Kowace shekara, bayan nazarin gwaje-gwajen da wasu muhimman abubuwa, USFDA ta amince da kwayoyi, don haka masu ciwon daji za su iya gaskata cewa magani ya kusa. ..